MarketPulse

biomarkers

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Aclarion, Inc.

Aclarion Charts Path to Growth With 2026 Reimbursement Push and Clinical Readouts

Aclarion outlines 2026 priorities: pursuing regional insurance reimbursement, releasing CLARITY trial results in Q4 2026, and expanding Nociscan adoption. Strong balance sheet extends to 2028.
ACONACONWbalance sheetchronic low back pain
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Aclarion CEO to Showcase NOCISCAN Platform at LSI USA 2026 Conference

Aclarion CEO to present NOCISCAN platform at LSI USA 2026 investor conference, advancing AI-powered diagnostic technology for chronic low back pain identification.
ACONACONWchronic low back painhealthcare technology
BenzingaBenzinga··Vandana Singh

Tempus Expands Merck Partnership as AI Precision Medicine Gains Momentum

Tempus AI expands multi-year partnership with Merck to develop AI-driven precision medicine biomarkers, though stock declined 1.56% amid broader market weakness.
MRKTEMpersonalized medicineoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Clene Inc.

Clene Maps Out 2026 Regulatory Path for ALS Candidate CNM-Au8

Clene outlines 2026 regulatory milestones for ALS drug CNM-Au8, including FDA meeting, NDA submission, and Phase 3 trial, backed by $28 million funding.
CLNNFDA approvalclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Abivax Sa

Abivax Demonstrates Anti-Fibrotic Potential of Obefazimod at ECCO 2026

Abivax presented evidence that obefazimod shows anti-fibrotic potential in IBD treatment with good safety profile. Phase 3 results expected mid-2026.
ABVXPhase 3 clinical trialsbiomarkers
GlobeNewswire Inc.GlobeNewswire Inc.··Custom Market Insights

ALS Therapeutics Market Poised to More Than Double by 2035

ALS therapeutics market to more than double by 2035, reaching $1.96 billion. Growth driven by genetic therapies, improved diagnostics, and disease awareness.
CYTKBIIBIONSAMLXrare diseasegene therapy